These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34268454)

  • 1. Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.
    Yuen KCJ; Mortensen MJ; Azadi A; Fonkem E; Findling JW
    Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00246. PubMed ID: 34268454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adrenal Insufficiency: Immune Checkpoint Inhibitors and Immune-Related Adverse Event Management.
    Hobbs KB; Yackzan S
    Clin J Oncol Nurs; 2020 Jun; 24(3):240-243. PubMed ID: 32441673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
    Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
    J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 pandemic and adrenals: deep insights and implications in patients with glucocorticoid disorders.
    Cozzolino A; Hasenmajer V; Newell-Price J; Isidori AM
    Endocrine; 2023 Oct; 82(1):1-14. PubMed ID: 37338722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenal Insufficiency and Glucocorticoid Use During the COVID-19 Pandemic.
    Almeida MQ; Mendonca BB
    Clinics (Sao Paulo); 2020; 75():e2022. PubMed ID: 32555949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors.
    Yeung SJ; Qdaisat A; Bischof JJ; Caterino JM; Kyriacou DN; Coyne Md C
    Am J Emerg Med; 2024 Jun; 80():227.e1-227.e5. PubMed ID: 38705758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
    Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
    Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk assessment, diagnosis, and treatment of cancer treatment-related adrenal insufficiency.
    Hayes AG; Rushworth RL; Torpy DJ
    Expert Rev Endocrinol Metab; 2022 Jan; 17(1):21-33. PubMed ID: 34979842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
    Manaka K; Sato J; Takeuchi M; Watanabe K; Kage H; Kawai T; Sato Y; Miyagawa T; Yamada D; Kume H; Sato S; Nagase T; Iiri T; Nangaku M; Makita N
    Sci Rep; 2021 Jun; 11(1):11617. PubMed ID: 34078988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
    Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
    Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.
    Kotwal A
    Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):427-434. PubMed ID: 34183541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis.
    Bando H; Yamamoto M; Urai S; Motomura Y; Sasaki Y; Ohmachi Y; Kobatake M; Tsujimoto Y; Oi-Yo Y; Suzuki M; Yamamoto N; Takahashi M; Fukuoka H; Iguchi G; Ogawa W
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38418395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: A retrospective cohort study.
    Cai Q; Wu W; Li R; Li X; Xu Q; Zhao L; Lv Q
    Int Immunopharmacol; 2024 Jan; 127():111337. PubMed ID: 38064811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitor-Induced Adrenalitis and Primary Adrenal Insufficiency: Systematic Review and Optimal Management.
    Shi Y; Shen M; Zheng X; Yang T
    Endocr Pract; 2021 Feb; 27(2):165-169. PubMed ID: 33554872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
    Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study.
    Takayasu S; Mizushiri S; Watanuki Y; Yamagata S; Usutani M; Nakada Y; Asari Y; Murasawa S; Kageyama K; Daimon M
    Sci Rep; 2022 Jan; 12(1):1294. PubMed ID: 35079086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects.
    Martella S; Lucas M; Porcu M; Perra L; Denaro N; Pretta A; Deias G; Willard-Gallo K; Parra HS; Saba L; Scartozzi M; Wekking D; Kok M; Aiello MM; Solinas C
    Semin Oncol; 2023 Dec; 50(6):144-148. PubMed ID: 38151399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibition in COVID-19: risks and benefits.
    Pezeshki PS; Rezaei N
    Expert Opin Biol Ther; 2021 Sep; 21(9):1173-1179. PubMed ID: 33543652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
    Hijmering-Kappelle LBM; Hiltermann TJN; Bensch F
    Clin Lung Cancer; 2022 Mar; 23(2):143-150. PubMed ID: 35034861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.